Monopar and NorthStar Amend & Extend Collaboration
2024年6月11日 - 8:30PM
Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage
radiopharma company, and NorthStar Medical Radioisotopes, LLC, a
global innovator in development and commercial production of
medical radioisotopes, today announced an amendment and expansion
to their existing collaboration. Under terms of the revised
collaboration, the Companies entered into a long-term,
non-exclusive master supply agreement for NorthStar to provide
Monopar with the powerful therapeutic radioisotope actinium-225
(Ac-225). The amendment builds on NorthStar’s significant
investment in Ac-225 manufacturing and Monopar’s promising
preclinical therapeutic results with Ac-225 in its lead MNPR-101
radiopharma program.
The amendment also clarifies certain economic terms and those
related to jointly developed intellectual property rights for
Monopar’s MNPR-101 for radiopharmaceutical use. Monopar has
acquired those rights from NorthStar, together with certain broad,
jointly developed intellectual property pertaining to MNPR-101,
giving Monopar full ownership and title to its lead MNPR-101
radiopharmaceutical platform. Both companies will share ownership
of the filed patent application on the use of PCTA as a linker with
Ac-225, which has shown superior binding and yield with Ac-225 over
the current industry-leading linker, DOTA.
“We are excited about the evolution of our collaboration, the
promising potential of the MNPR-101 radiopharma platform, and the
long-term access to a high-quality source of Ac-225 that can
support our current development programs and potential future
commercial products,” said Chandler Robinson, MD, Monopar’s Chief
Executive Officer.
“Using our proprietary electron accelerator technology,
NorthStar is poised to be the first commercial-scale producer of
non-carrier added (n.c.a.) Ac-225. We’re delighted to continue and
extend our collaboration with Monopar and support development of
its exciting MNPR-101 radiopharma platform focused on therapeutic
agents to treat aggressive cancers,” said Frank Scholz, PhD,
NorthStar’s Chief Executive Officer.
About Monopar Therapeutics Inc.
(Monopar)
Monopar Therapeutics is a clinical-stage radiopharmaceutical
company focused on developing innovative treatments for cancer
patients, including Phase 1-stage MNPR-101-Zr for imaging advanced
cancers and late preclinical-stage MNPR-101
radio-immuno-therapeutic (RIT) for the treatment of advanced
cancers. For more information, visit: www.monopartx.com.
About NorthStar Medical Radioisotopes, LLC
(NorthStar)
NorthStar Medical Radioisotopes is a commercial-stage
radiopharmaceutical company at the forefront of advancing patient
care by utilizing novel technologies to produce commercial-scale
radioisotopes that, once attached to a molecule, have the ability
to detect and treat cancer and other serious diseases. NorthStar’s
expanding industry-leading position in the emerging field of
radiopharmaceutical therapy is supported by its unique capabilities
in the sophisticated production of radioisotopes, proven management
team, and state-of-the-art, environmentally preferable
technologies. NorthStar routinely produces copper-67 (Cu-67) and is
poised to be the first commercial-scale producer of
non-carrier-added (n.c.a.) actinium-225 (Ac-225). The Company’s
Radiopharmaceutical Contract Development and Manufacturing
Organization (CDMO) services unit provides customized service
offerings and specialized radiopharmaceutical expertise to help
biopharmaceutical companies rapidly advance their development and
commercial programs. For more information about NorthStar’s
comprehensive portfolio and patient-focused services, visit:
www.northstarnm.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. The words “may,” “will,” “could,” “would,” “should,”
“expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,”
“predict,” “project,” “potential,” “continue,” “target” and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Examples of these forward-looking statements
include statements concerning: that NorthStar will provide
actinium-225 for Monopar’s development and potential future
commercial programs; the promising potential of Monopar’s MNPR-101
radiopharma platform, and the long-term access to a high-quality
source of Ac-225 that can support Monopar’s current development
programs and potential future commercial products; that NorthStar
is poised to be the first commercial-scale producer of non-carrier
added (n.c.a.) Ac-225; and that NorthStar will continue to support
development of Monopar’s exciting MNPR-101 radiopharma platform
focused on therapeutic agents to treat aggressive cancers. The
forward-looking statements involve risks and uncertainties
including, but not limited to: that Monopar’s and shared
intellectual property may not result in allowed patents; that if
allowed, the patents may be too narrow in scope to provide
protection needed to successfully develop the radiopharma program;
that NorthStar may not be able to supply Ac-225 at quantities
needed, if at all; that NorthStar may not be the first
commercial-scale producer of n.c.a. Ac-225; that Monopar may expend
available funds sooner than anticipated or require additional
funding due to change in circumstances or unanticipated events;
that future preclinical or clinical data will not be as promising
as the data to date; not successfully enrolling the MNPR-101-Zr
Phase 1 clinical trial if at all; that MNPR-101-Zr and/or MNPR-101
conjugated to a therapeutic radioisotope may cause unexpected
serious adverse effects or fail to image or be effective against
the cancer tumors in humans; and the significant general risks and
uncertainties surrounding the research, development, regulatory
approval, and commercialization of imaging agents and therapeutics.
Actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks are described
more fully in Monopar's filings with the Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Monopar
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made. Any forward-looking statements contained in
this press release represent Monopar’s and/or NorthStar’s views
only as of the date hereof and should not be relied upon as
representing its views as of any subsequent date.
CONTACTS:
For Monopar Therapeutics Inc.Investor
RelationsKim R. TsuchimotoChief Financial
Officerkimtsu@monopartx.com
Follow Monopar on social media for updates:X (formerly Twitter):
@MonoparTx LinkedIn: Monopar Therapeutics
For NorthStar Medical Radioisotopes, LLC
:Investor Relations:Paul EstremExecutive Vice President
and Chief Financial Officerpestrem@northstarnm.com
Media/Corporate:Alison HessVice President, Chief of
Staffahess@northstarnm.com
Monopar Therapeutics (NASDAQ:MNPR)
過去 株価チャート
から 5 2024 まで 6 2024
Monopar Therapeutics (NASDAQ:MNPR)
過去 株価チャート
から 6 2023 まで 6 2024